| 货号 | 12053S |
| 反应种属 | Human/Mouse/Rat/Monkey |
| 来源宿主 | Rabbit |
| 应用 | W/IP/IHC-P |
| 目标/特异性 | RCAS1 (D6P5J) Rabbit mAb recognizes endogenous levels of total RCAS1 protein. |
| 使用方法 | WB(1:1000) IP (1:200) IHC-P (1:1600) |
| 供应商 | CST |
| 背景 | Receptor binding cancer antigen expressed on SiSo cells (RCAS1) is also known as estrogen receptor-binding fragment-associated gene 9 (EBAG9). Originally identified as an estrogen-inducible gene (1), RCAS1 was recently found to play a novel role in the adaptive immune response by negatively regulating the cytolytic activity of cytotoxic T lymphocytes (CTLs) (2). RCAS1 is conserved in phylogeny and is ubiquitously expressed in most human tissues and cells (3,4). There is evidence that tissue expression of RCAS1 is increased in a variety of malignancies, including cancers of the gastrointestinal tract, liver, lung, breast, ovary, endometrium, and cervix. Research studies have shown that levels of RCAS1 tissue expression are negatively correlated with the prognosis of patients harboring the aforementioned malignancies (4). It is also noteworthy that research studies have detected elevated levels of RCAS1 in the sera of cancer patients (4). Initial studies indicated that RCAS1 was secreted from cancer cells and functioned as a ligand for a putative receptor expressed on NK cells, as well as T and B lymphocytes, inducing their apoptosis, which enabled cancer cells to evade immune surveillance (5,6). Subsequent studies have identified RCAS1 as a type III transmembrane Golgi protein with the ability to regulate vesicle formation, secretion, and protein glycosylation (2,7-9). Indeed, it has been shown that RCAS1 overexpression negatively regulates the cytolytic function of CTLs by negatively regulating protein trafficking from the trans-Golgi to secretory lysosomes (2). Furthermore, RCAS1 overexpression delays vesicle transport from the ER to Golgi and causes components of the ER quality control and glycosylation machinery to mislocalize. As a consequence, RCAS1 induces the deposition of tumor-associated glycan antigens on the cell surface, which are thought to contribute to tumor pathogenesis through the mediation of adhesion, invasion, and metastasis (8,9). |
| 存放说明 | -20C |
| 计算分子量 | 32 |
Western blot analysis of extracts from various cell lines using RCAS1 (D6P5J) Rabbit mAb. Western blot方法检测多种细胞系的提取物，使用的抗体为RCAS1 (D6P5J) XP® Rabbit mAb兔单抗。 | |
Western blot analysis of extracts from 293T cells, mock transfected (-) or transfected with a construct expressing Myc/DDK-tagged full-length human RCAS1 (hRCAS1-Myc/DDK; +), using RCAS1 (D6P5J) Rabbit mAb. Western blot方法检测293T细胞提取物，细胞分别用空白对照（-）或构建的带有Myc/DDK标签的全长人RCAS1 (hRCAS1-Myc/DDK; +)转染，使用的抗体为 RCAS1 (D6P5J) Rabbit mAb兔单抗。 | |
Immunoprecipitation of RCAS1 from Jurkat cell extracts using Rabbit (DA1E) mAb IgG XP® Isotype Control #3900 (lane 2) or RCAS1 (D6P5J) Rabbit mAb (lane 3). Lane 1 is 10% input. Western blot detection was performed using RCAS1 (D6P5J) Rabbit mAb. 免疫沉淀法检测 Jurkat细胞提取物中的RCAS1，使用抗体为Rabbit (DA1E) mAb IgG XP® Isotype Control #3900（泳道 2）或 RCAS1 (D6P5J) Rabbit mAb(泳道3)。泳道1为10% input对照。 Western blot 检测中使用的是RCAS1 (D6P5J) Rabbit mAb兔单抗。 | |
Immunohistochemical analysis of paraffin-embedded human breast carcinoma using RCAS1 (D6P5J) Rabbit mAb. 免疫组化检测石蜡包埋的人乳腺癌，所使用的抗体为Histone RCAS1 (D6P5J) Rabbit mAb兔单抗。 | |
Immunohistochemical analysis of paraffin-embedded human lung carcinoma using RCAS1 (D6P5J) Rabbit mAb in the presence of control peptide (left) or antigen-specific peptide (right). 免疫组化分别检测在对照多肽（左）或抗原特异性多肽（右）存在的情况下石蜡包埋的人肺癌组织，所使用的抗体为RCAS1 (D6P5J) Rabbit mAb兔单抗。 | |
Immunohistochemical analysis of paraffin-embedded mouse brain using RCAS1 (D6P5J) Rabbit mAb. 免疫组化检测石蜡包埋的小鼠脑组织，所使用的抗体为RCAS1 (D6P5J) Rabbit mAb兔单抗。 |
